Japanese pharma group Shionogi (TYO: 4507) has struck a licence and collaboration deal with Roche (ROG: SIX) for the development and commercialization of its flu drug candidate S-033188.
The treatment is a cap-dependent endonuclease inhibitor and is expected to be a one-time, single-dose therapy.
Shionogi said S-033188 had the potential to be more convenient and, with a novel mechanism of action, more effective than existing flu products which tend to be neuraminidase inhibitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze